Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

The 2011 Biotech Graveyard
Fierce Biotech
Monday, October 31, 2011 - 11:46am
tags:
Advanced Life Sciences, Altair, Ambrilla, ARYx, PeptImmune, Phenomix, Tolerx, Transdel
Melbourne woman leads Australian class action on cancer vaccine Gardasil
Herald Sun, Australia
Monday, October 31, 2011 - 11:40am
tags:
Australia, Class Action Lawsuit, Merck, HPV, Gardasil
Obama to order new FDA action on drug shortages
Fierce Pharma
Monday, October 31, 2011 - 11:35am
tags:
drug shortages, FDA, Obama
November Catalysts for Biotech and Drug Stocks
Minyanville
Monday, October 31, 2011 - 11:34am
tags:
FDA, Regeneron, Vertex, Pharmasset, pSivida, Alimera, Salix, Teva Pharmaceuticals, BioSante, Transcept
Geron And InVivo: The Race To Cure Paralysis
Seeking Alpha
Monday, October 31, 2011 - 11:32am
tags:
Geron, InVivo, spinal cord injury, embryonic stem cells
Why Speculators Are Buzzing About OxiGENE
Seeking Alpha
Monday, October 31, 2011 - 11:30am
tags:
Oxigene, Zybrestat
Pacira: Exparel Approval Easy, Selling Painkiller Harder Challenge
TheStreet.com
Monday, October 31, 2011 - 11:29am
tags:
Pacira, EXPAREL, painkillers
Merck Can Block Teva on Generic Temodar as Court Rejects Appeal
Bloomberg
Monday, October 31, 2011 - 11:28am
tags:
Teva Pharmaceuticals, generics, Temodar, Merck, brain cancer
1 Reason the Street Should Love Amgen's Earnings
Motley Fool
Monday, October 31, 2011 - 11:28am
tags:
earnings, Amgen
Former Pfizer Rep Won’t Return $411K Severance
Pharmalot
Monday, October 31, 2011 - 11:27am
tags:
Pfizer, drug reps, severance
FDA Gives Favorable Review to SHARP Ahead of Vytorin Advisory Panel
Forbes
Monday, October 31, 2011 - 10:51am
tags:
Vytorin, Merck, FDA, advisory panels, SHARP
Dividend Yield Vs. Dividend Growth: Are You Better Off With Eli Lilly Or Procter & Gamble?
Seeking Alpha
Sunday, October 30, 2011 - 12:53pm
tags:
Eli Lilly, Proctor & Gamble
China Biotech Week In Review: BioBay Park Forms Partnership With Roche, Harvard
Seeking Alpha
Sunday, October 30, 2011 - 12:52pm
tags:
Biobay Park, ShangPharma, WuXi PharmaTech, Novartis, Shanghai Modern Hasen Pharma, Lepu Medical Technology
Lack of antibiotic research a looming crisis
The Day, CT
Sunday, October 30, 2011 - 12:50pm
tags:
antibiotics, GAIN Act
Why Bristol-Myers Is Not Overvalued
Seeking Alpha
Sunday, October 30, 2011 - 12:46pm
tags:
Bristol-Myers Squibb
Attention On Human Genome As Speculation, Media Influences Come Into Play
Seeking Alpha
Sunday, October 30, 2011 - 12:45pm
tags:
Human Genome Sciences
Merck Sells Its Interest in Johnson & Johnson-Merck Consumer Pharmaceuticals
Benzinga
Sunday, October 30, 2011 - 12:44pm
tags:
Merck, JNJ
SuperGen, Inc. Changes Name to Astex Pharmaceuticals, Inc., Announces New Stock Ticker Symbol and New Website
Benzinga
Sunday, October 30, 2011 - 12:43pm
tags:
Supergen, Astex
All Eyes On Dendreon With Earnings Set For Wednesday
Seeking Alpha
Sunday, October 30, 2011 - 12:41pm
tags:
Dendreon, earnings
9 Biotech Stocks Trading At Steepest Discount To Target Price
Seeking Alpha
Sunday, October 30, 2011 - 12:40pm
tags:
Inhibitex, Affymax, Alnylam, Incyte, Ziopharm, Array Biopharma, Ariad Pharmaceuticals, Xoma, Complete Genomics

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.